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original article

Economic Impact of Ventilator-Associated Pneumonia
in a Large Matched Cohort
Marin H. Kollef, MD;1 Cindy W. Hamilton, PharmD;2 Frank R. Ernst, PharmD, MS3

objective. To evaluate the economic impact of ventilator-associated pneumonia (VAP) on length of stay and hospital costs.
design.

Retrospective matched cohort study.

setting. Premier database of hospitals in the United States.
patients. Eligible patients were admitted to intensive care units (ICUs), received mechanical ventilation for ≥2 calendar-days, and were
discharged between October 1, 2008, and December 31, 2009.
methods. VAP was defined by International Classification of Diseases, Ninth Revision (ICD-9), code 997.31 and ventilation charges for
≥2 calendar-days. We matched patients with VAP to patients without VAP by propensity score on the basis of demographics, administrative
data, and severity of illness. Cost was based on provider perspective and procedural cost accounting methods.
results. Of 88,689 eligible patients, 2,238 (2.5%) had VAP; the incidence rate was 1.27 per 1,000 ventilation-days. In the matched
cohort, patients with VAP (n p 2,144) had longer mean durations of mechanical ventilation (21.8 vs 10.3 days), ICU stay (20.5 vs 11.6
days), and hospitalization (32.6 vs 19.5 days; all P ! .0001 ) than patients without VAP (n p 2,144 ). Mean hospitalization costs were $99,598
for patients with VAP and $59,770 for patients without VAP (P ! .0001 ), resulting in an absolute difference of $39,828. Patients with VAP
had a lower in-hospital mortality rate than patients without VAP (482/2,144 [22.5%] vs 630/2,144 [29.4%]; P ! .0001).
conclusions. Our findings suggest that VAP continues to occur as defined by the new specific ICD-9 code and is associated with a
statistically significant resource utilization burden, which underscores the need for cost-effective interventions to minimize the occurrence
of this complication.
Infect Control Hosp Epidemiol 2012;33(3):250-256

Ventilator-associated pneumonia (VAP) is of concern because
of its frequency and economic burden. Pneumonia is the most
common discharge diagnosis in the United States.1 Between
1997 and 2008, use of respiratory intubation and mechanical
ventilation (MV) escalated, and the cost of respiratory failure
grew at 2–3 times those of total hospital costs.1 Cost is relevant
to providers because VAP is among the conditions being considered for nonreimbursement by the Centers for Medicare
and Medicaid Services.
VAP prolongs length of stay (LOS) and increases hospital
costs;2-5 however, estimates are derived from data collected
between the mid-1980s and 2004 and may not reflect the
impact of inflation. On the other hand, estimates may not
reflect the impact of economic pressure to minimize LOS or
use new preventive strategies. In addition, previous studies
often relied on nonspecific diagnostic criteria, such as the use
of MV and the diagnostic code for bacterial pneumonia.
We hypothesized that VAP—as defined by the specific International Classification of Diseases, Ninth Revision, clinical

modification (ICD-9) code 997.31 introduced in 2008—would
be associated with increased LOS and hospital costs. To test
this hypothesis, we performed a matched cohort study of the
Premier database and evaluated the impact of VAP on LOS in
the hospital and intensive care unit (ICU), duration of MV,
and hospital costs. We also calculated the frequency of VAP
and in-hospital mortality.

methods
To evaluate the economic impact of VAP on hospitals, we
performed a retrospective matched cohort study of the Premier
research database, which involves approximately 400 of 12,500
hospitals in the Premier healthcare alliance. The study was
conducted in compliance with US federal regulations, the
Health Insurance Portability and Accountability Act, and the
Helsinki Declaration. Patient-specific data were deidentified.
To be included in the study, adults (age ≥18 years) had to
have spent at least 1 day in the ICU and to have been dis-
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table 1. Demographic, Admission, and Discharge Data
All patients
Characteristic
Age, years
18–44
45–64
65–79
≥80
Mean Ⳳ SD
Sex, male
Race
White
Black
Hispanic
Other/unknown
Primary payor
Medicare
Medicaid
Managed care
Commercial
Other
Admission source
Physician referral
Transfer from another health facility
Emergency room
Other or unknown
Admission type
Emergency
Urgent
Elective
Trauma center/other/unknown
Discharge status
Expired
Transferred to home
Transferred to skilled nursing facility
Transferred to rehab
Transferred to short-term hospital
Other or unknown
APR-DRG severity of illness
Minor or moderate
Major
Extreme
APR-DRG risk of mortality
Minor or moderate
Major
Extreme
Geographic area
Northeast
Midwest
South
West
Urban population
Teaching hospital
Hospital size, beds
6–199
200–299
300–499
≥500

With VAP
(N p 2,238)

Without VAP
(N p 86,451)

459 (20.5)
860 (38.4)
669 (29.9)
250 (11.2)
62.9 Ⳳ 16.6
1,415 (63.2)

11,730 (13.6)
31,360 (36.3)
28,515 (33.0)
14,846 (17.2)
58.8 Ⳳ 17.5
46,642 (54.0)

1,343
432
159
304

(60.0)
(19.3)
(7.1)
(13.6)

54,351
13,310
4,088
14,702

(62.3)
(15.4)
(4.7)
(17.0)

1,044
391
399
171
233

(46.7)
(17.5)
(17.8)
(7.6)
(10.4)

49,150
10,402
13,185
5,176
8,538

(56.9)
(12.0)
(15.3)
(6.0)
(9.9)

329
532
1,293
84

(14.7)
(23.8)
(57.8)
(3.8)

13,223
14,883
57,109
1,236

(15.3)
(17.2)
(66.1)
(1.4)

1,558
317
239
124

(69.6)
(14.2)
(10.7)
(5.5)

62,277
12,697
9,348
2,129

(72.0)
(14.7)
(10.8)
(2.5)

498
378
440
273
153
496

(22.3)
(16.9)
(19.7)
(12.2)
(6.8)
(22.2)

25,053
23,177
14,737
6,492
4,409
12,583

(29.0)
(26.8)
(17.1)
(7.5)
(5.1)
(14.6)

Matched cohort
P

With VAP
(N p 2,144)

Without VAP
(N p 2,144)

412 (19.2)
831 (38.8)
653 (30.5)
248 (11.6)
59.3 Ⳳ 17.3
1,337 (62.4)

404 (18.8)
850 (39.7)
651 (30.4)
239 (11.2)
59.4 Ⳳ 17.1
1,335 (62.3)

1,311
406
133
294

(61.2)
(18.9)
(6.2)
(13.7)

1,332
408
122
282

(62.1)
(19.0)
(5.7)
(13.2)

1,027
364
383
159
211

(47.9)
(17.0)
(17.9)
(7.4)
(9.8)

1,028
363
397
150
206

(48.0)
(16.9)
(18.5)
(7.0)
(9.6)

319
496
1,257
72

(14.9)
(23.1)
(58.6)
(3.4)

296
489
1,293
66

(13.8)
(22.8)
(60.3)
(3.1)

1,517
310
226
91

(70.8)
(14.5)
(10.5)
(4.2)

1,554
291
209
90

(72.5)
(13.6)
(9.8)
(4.2)

482
356
426
260
149
471

(22.5)
(16.6)
(19.9)
(12.1)
(7.0)
(22.0)

630
561
366
191
82
314

(29.4)
(26.2)
(17.1)
(8.9)
(3.8)
(14.6)

P

!.0001

!.0001
!.0001

!.0001

!.0001

!.0001

!.0001

!.0001

!.0001

3 (0.1)
116 (5.2)
2,119 (94.7)

1,337 (1.5)
9,828 (11.4)
75,286 (87.1)

71 (3.2)
538 (24.0)
1,629 (72.8)

4,670 (5.4)
19,797 (22.9)
61,984 (71.7)

380
614
969
275
168
1,478

(17.0)
(27.4)
(43.3)
(12.3)
(7.5)
(66.0)

14,596
19,227
37,433
15,195
8,630
41,221

(16.9)
(22.2)
(43.3)
(17.6)
(10.0)
(47.7)

116
195
752
1,175

(5.2)
(8.7)
(33.6)
(52.5)

8,099
12,019
33,924
32,409

(9.4)
(13.9)
(39.2)
(37.5)

3 (0.1)
112 (5.2)
2,029 (94.6)

2 (0.1)
99 (4.6)
2,043 (95.3)

62 (2.9)
499 (23.3)
1,583 (73.8)

41 (1.9)
490 (22.9)
1,613 (75.2)

362
581
932
269
1,979
1,388

(16.9)
(27.1)
(43.5)
(12.6)
(92.3)
(64.7)

357
567
949
271
1,980
1,386

(16.7)
(26.5)
(44.3)
(12.6)
(92.4)
(64.7)

114
194
727
1,109

(5.3)
(9.1)
(33.9)
(51.7)

108
196
728
1,112

(5.0)
(9.1)
(34.0)
(51.9)

!.0001

!.0001

!.0001
!.0001
!.0001

note. Data are number of discharges (%), unless otherwise indicated. APR-DRG, all patient refined diagnosis-related group;
SD, standard deviation; VAP, ventilator-associated pneumonia.
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table 2. Diagnostic Codes in All Patients
No. of discharges (%)
MS-DRG code
3

4

207
870
853

208
329

With VAP
(N p 2,238)

Without VAP
(N p 86,451)

MS-DRG 3: trach with MV ≥96 h with
major OR

658 (29.4)

7,005 (8.1)

MS-DRG 4: trach with MV ≥96 h without major OR

372 (16.6)

6,100 (7.1)

MS-DRG 207: respiratory diagnosis with
MV ≥96 h
MS-DRG 870: sepsis with MV ≥96 h

232 (10.4)

9,898 (11.4)

177 (7.9)

6,572 (7.6)

MS-DRG 853: infection with OR and
major complication

47 (2.1)

2,927 (3.4)

MS-DRG 208: respiratory diagnosis with
MV !96 h
MS-DRG 329: bowel procedure with major complication

39 (1.7)

9,782 (11.3)

35 (1.6)

2,480 (2.9)

Population
ECMO or tracheostomy with mechanical
ventilation ≥96 h or principal diagnosis
except face, mouth, and neck with major OR
Tracheostomy with mechanical ventilation
≥96 h or principal diagnosis except
face, mouth, and neck without major
OR
Respiratory system diagnosis with ventilator support ≥96 h
Septicemia or severe sepsis with mechanical ventilation ≥96 h
Infectious and parasitic diseases with OR
with major complication or
comorbidity
Respiratory system diagnosis with ventilator support !96 h
Major small and large bowel procedure
with major complication or
comorbidity

Abbreviated description

note. ECMO, extracorporeal membrane oxygenation; MS-DRG, Medicare severity diagnosis-related group; MV, mechanical ventilation;
OR, operating room procedure; trach, tracheostomy; VAP, ventilator-associated pneumonia.

charged from the hospital between October 1, 2008, and December 31, 2009. Patients on continuous MV were identified
using ICD-9 procedure codes 96.71 or 96.72; they also had
to have undergone MV for ≥2 calendar-days, as defined by
billing charges. VAP was defined by ICD-9 code 997.31.
Economic data were based on true hospital costs, including
direct and indirect medical costs (eg, fixed, variable, and overhead costs were indirect costs from an accounting perspective); indirect costs incurred by patients and their caregivers
were excluded. ICU costs were determined using room and
board billing (eg, coronary care unit and surgical, medical,
cardiac, and cardiovascular ICUs) and did not include stepdown or telemetry units. Cost analysis proceeded from the
hospital perspective. Cost data were obtained from hospital
accounting systems and reported to Premier. Most hospitals
used procedural cost accounting methods; ≤25% used ratios
of costs to charges and total patient-level charges. Actual costs
were available for each revenue department as well as for each
billing item. Patient billing codes for products and services
received during hospitalization were captured. In-hospital
mortality was indicated by a discharge status of expired.
Statistical Analysis
Categorical data were expressed as percentages of patients;
between-group differences (with vs without VAP) were compared using x2 or Fisher exact tests. Continuous data were
expressed as means and standard deviations; between-group

differences were compared using 1-way ANOVA. Statistical
analyses were conducted using WinSQL (Synametrics Technologies) and SAS (ver. 9.1; SAS Institute). All statistical tests
of comparison were 2 sided based on a ! .05. All analyses
were conducted for the overall VAP population as well as for
the 7 Medicare severity diagnosis-related groups (MS-DRGs)
with the highest volume of VAP patients.
Propensity score matching was used to adjust for betweengroup imbalances. Logistic regression was performed to estimate the propensity score for each patient using available
covariates, which were selected a priori and on the basis of
ability to maximize the receiver operator characteristic curve
of the selection model. Propensity scoring was used to match
each case patient with VAP to 1 control patient without VAP,
using a greedy algorithm,6,7 which matches the highest digit
in a hierarchical sequence until each case is matched; matching was performed at ≥4 digits. Patient characteristics used
in matching were age, gender, race/ethnicity, primary payor
type, attending physician specialty, admission source, admission type, 3M all patient refined (APR)-DRG severity of illness, and APR-DRG risk of mortality. Hospital characteristics
were geographic region, bed size, urban/rural status, and
teaching status.
Matching was conducted on the overall VAP population
and on the 7 MS-DRGs with the most VAP patients. Match
quality was evaluated using a quantile distribution of the
propensity scores for each population as well as univariate
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figure 1. Duration of mechanical ventilation, intensive care unit (ICU) stay, and hospital stay in a matched cohort of 2,144 patients with
ventilator-associated pneumonia (VAP) and 2,144 patients without VAP. All P ! .0001 for between-cohort differences in durations of
hospitalization, ICU stay, and mechanical ventilation.

ANOVA to test for between-group differences. Tests of comparison of each of patient and hospital variables were conducted using the matched population to further test betweengroup imbalances in covariates.

results
All Patients
Of 88,689 patients who had undergone MV for ≥2 calendardays, 2,238 (2.5%) had the ICD-9 code for VAP. The incidence
rate was 1.27 cases per 1,000 MV-days. Patients with VAP
were older and more likely to be male than patients without
VAP (Table 1). Patients with VAP were more likely to have
been transferred from another healthcare facility and to have
been discharged to skilled nursing or rehabilitation facilities.
Patients with VAP represented 161 different MS-DRGs, but
the 7 most common comprised 70% of all patients with VAP
(Table 2). The most common in patients with VAP was MSDRG 3 (29.4%; for descriptions of abbreviated diagnostic
codes, see Table 2).
Matched Cohort
A total of 2,144 case patients with VAP were matched with
2,144 control patients without VAP, representing 96% of the
VAP population. There were no between-group differences
in patient or hospital characteristics except for discharge
status, which was excluded from matching because mortality
was an outcome of interest (see Table 1). Matching captured
86%–100% of the VAP population for the 7 MS-DRG
populations.
Patients with VAP had longer durations of MV (mean Ⳳ
standard deviation [SD], 21.8 Ⳳ 25.0 vs 10.3 Ⳳ 10.5 days),
ICU stay (20.5 Ⳳ 15.8 vs 11.6 Ⳳ 10.3 days), and hospitali-

zation (32.6 Ⳳ 31.9 vs 19.5 Ⳳ 17.9 days; all P ! .0001) than
patients without VAP (Figure 1). At least 1 of these 3 outcomes (duration of MV, ICU stay, or hospitalization) was
longer for patients with VAP in 6 of 7 MS-DRG populations;
the exception was MS-DRG 329 (authors’ online Table 1
available at their Web site http://hamiltonhouseva.com/
KollefVAPeconomicsICHEtables.pdf).
Patients with VAP had higher mean costs for hospitalization, pharmacy, antibiotics, vancomycin, propofol, ventilation
both overall and in the ICU, respiratory therapy, and chest
x-rays (Table 3). For example, mean hospitalization costs were
$99,598 for patients with VAP and $59,770 for patients without VAP (P ! .0001), resulting in an absolute difference of
$39,828 between these matched cohorts. Mean hospitalization
costs were higher for patients with VAP than for those without
in the following MS-DRG populations: MS-DRG 4, MS-DRG
870, MS-DRG 853, and MS-DRG 207 (Table 4). Selected
costs—such as those related to antibiotic use or pharmacy as
a whole, MV, respiratory therapy, or chest x-rays—were also
higher in patients with VAP, especially in MS-DRG 4, MSDRG 870, and MS-DRG 853 (authors’ online Table 2
available at their Web site http://hamiltonhouseva.com/
KollefVAPeconomicsICHEtables.pdf).
Patients with VAP had a lower overall in-hospital mortality
rate than patients without VAP (482/2,144 [22.5%] vs 630/
2,144 [29.4%]; P ! .0001; data not shown). There were no
between-group differences in 30-day all-cause readmissions,
excluding mortality (287/1,662 [17.3%] vs 271/1,514 [17.9%];
P p .64). There were no between-group differences in any
of the MS-DRG populations except MS-DRG 853. In that
population, patients with VAP had higher rates of mortality
(19/46 [41.3%] vs 7/46 [15.2%]; P p .01) and 30-day all-
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table 3. Costs in a Matched Cohort of 2,144 Patients with Ventilator-Associated Pneumonia (VAP)
and 2,144 Patients without VAP
Cost, dollars, mean Ⳳ SDa
Outcome type
Hospitalization
Nursing time
Pharmacy
Antibiotic
Vancomycin
Propofol for sedation
Ventilator
Ventilator in ICU
Respiratory therapy
Chest x-rays

With VAP
99,598
3,369
14,345
1,947
327
947
4,710
3,716
2,650
1,762

Ⳳ
Ⳳ
Ⳳ
Ⳳ
Ⳳ
Ⳳ
Ⳳ
Ⳳ
Ⳳ
Ⳳ

86,359
16,487
16,992
4,095
564
1,768
6,251
4,479
4,007
1,594

Without VAP

P

Ⳳ
Ⳳ
Ⳳ
Ⳳ
Ⳳ
Ⳳ
Ⳳ
Ⳳ
Ⳳ
Ⳳ

!.0001

59,770
2,980
8,547
1,011
248
585
2,184
1,909
1,496
1,009

58,278
14,109
14,497
2,039
420
1,202
2,807
2,304
2,539
958

.568
!.0001
!.0001
!.0001
!.0001
!.0001
!.0001
!.0001
!.0001

Difference in dollars (%)
39,828
389
5,798
936
79
362
2,526
1,807
1,154
753

(40.0)
(11.5)
(40.4)
(48.1)
(24.2)
(38.2)
(53.6)
(48.6)
(43.5)
(42.7)

note. ICU, intensive care unit; SD, standard deviation.
a
Costs represent medical direct and indirect costs (not Medicare charges). Costs were not additive
(eg, antibiotic and propofol costs were a subset of pharmacy costs).

cause readmissions, excluding mortality (9/46 [19.6%] vs 3/
46 [6.5%]; P p .01).

discussion
Our database analysis revealed VAP in 2.6% of 88,689
hospitalized patients who had undergone MV ≥2 calendardays. A unique feature of our study was the analysis of
VAP rate by MS-DRG population. The highest rates were
8.6% in patients with MS-DRG 3 and 5.7% in those with
MS-DRG 4, which is consistent with the prolonged duration
of MV in these populations (authors’ online Table 1
available at their Web site http://hamiltonhouseva.com/
KollefVAPeconomicsICHEtables.pdf). In patients matched by
propensity scores comprising severity of illness and other
possible confounders, VAP added approximately $40,000 to
absolute hospital costs and at least 10 days to the absolute
durations of MV, ICU stay, and overall hospitalization.
Our findings add to those of previous studies involving
large databases2,3 or literature reviews of mechanically ventilated patients;4,5 however, differences in study methods may
have affected VAP rates. Rello et al2 reported that VAP occurred in 9.3% of 9,080 ICU patients who had undergone
MV ≥24 hours and who had ICD-9 codes for bacterial pneumonia. Similarly, Safdar et al4 reported a cumulative incidence
of 9.7% in 48,112 patients in 38 cohort or nonrandomized
studies, whereas the incidence was 22.8% in 4,802 patients
in 51 randomized studies. Buczko3 reported VAP in 24.5%
of 13,759 Medicare patients in long-term care hospitals. These
between-study differences could be attributable to differences
in study populations, diagnostic criteria, use of preventive
strategies, and other factors. Our low rate is consistent with
the use of a VAP-specific code, which probably reduced the
risk of false positive identification. Alternatively, the new diagnostic code may have had poor sensitivity.
The LOS in our study was within the range of previous
studies involving large databases2,3 or a literature review;4 LOS

was not reported in the other literature review.5 Specifically,
the 10-day additional LOS in our study was generally consistent with that in 1 of the database studies.2 VAP added 6.1
days to the mean ICU stay in the literature review.4 Not
surprisingly, LOS was prolonged for patients in long-term
care hospitals, where total LOS was 46.5 days for patients
with VAP and 43.8 days for patients without VAP.3
The incremental hospital cost of VAP was higher in our
study than in previous studies. VAP was associated with attributable hospital costs of $10,000–$13,500 per 5–7 days in
a review of studies conducted between 1984 and 2002.4 In
the remaining studies, VAP was associated with additional
charges of approximately $15,000 in long-term care patients
in 20043 and of $40,000 in the database analysis conducted
in the late 1990s.2 These between-study differences are attributable to timing differences, with inflation contributing
to the higher cost in our more recent study. In addition,
charges in 2 studies2,3 are inherently higher than costs in our
study and in another study.4
Another unique feature of our study was the breakdown
of costs for expense categories. Many costs were higher among
patients with VAP than among patients without VAP, especially pharmacy, MV, respiratory therapy, and chest xrays—all of which were at least 40% higher. The increase in
nursing time, however, was not significantly higher among
cases. Restrepo et al8 also reported higher breakdown costs
in a matched cohort study of 30 case patients and 90 control
patients. As in our study, the costs of overall hospitalization
and respiratory therapy were higher among patients with
VAP; however, between-cohort differences in pharmacy were
not statistically significant, possibly because of sample size.
Additional categories with significant between-cohort differences were cardiology, operating room, electrocardiogram,
and recovery room; we did not collect data on these
categories.
Mortality was lower in patients with VAP than patients
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Hospitalization Costs in a Matched Cohort of Patients with Ventilator-Associated Pneumonia (VAP) and Patients without VAP
Cost, dollars, mean Ⳳ SDa

MS-DRG code
3

4
207
870
853
208
329

Population

With VAP

Without VAP

P

ECMO or tracheostomy with mechanical ventilation ≥96 h or
principal diagnosis except face, mouth, and neck with major
OR
Tracheostomy with mechanical ventilation ≥96 h or principal
diagnosis except face, mouth, and neck without major OR
Respiratory system diagnosis with ventilator support ≥96 h
Septicemia or severe sepsis with mechanical ventilation ≥96 h
Infectious and parasitic diseases with OR procedure with major
complication or comorbidity
Respiratory system diagnosis with ventilator support !96 h
Major small and large bowel procedure with major complication
or comorbidity

153,625 Ⳳ 105,696

142,827 Ⳳ 125,400

.113

112,865 Ⳳ 77,784

83,187 Ⳳ 44,590

!.0001

46,928 Ⳳ 34,145
59,238 Ⳳ 58,111
103,082 Ⳳ 91,291

41,627 Ⳳ 24,701
44,642 Ⳳ 25,851
66,972 Ⳳ 51,444

.060
.005
.022

25,612 Ⳳ 20,324
90,799 Ⳳ 62,532

17,593 Ⳳ 8,269
69,767 Ⳳ 77,229

.027
.215

note. ECMO, extracorporeal membrane oxygenation; MS-DRG, Medicare Severity diagnosis-related group; OR, operating room procedure;
SD, standard deviation.

without VAP (22.5% vs 29.4%; P ! .0001), which contrasts
with popular perception but has been previously reported.
Only 14 of the studies involving large databases2,3 or literature
reviews4,5 revealed an association between VAP and mortality
(odds ratio [OR], 2.03 [95% confidence interval (CI),
1.16–3.56]). In the remaining studies, between-cohort differences were not significant2,3 or mortality was not reported.5
This is not surprising in view of the results of a recent systematic review.9 The relative risk of mortality was 1.27 (95%
CI, 1.15–1.39) in a pooled analysis of 52 observational studies
of patients with and without VAP; however, considerable heterogeneity confounded interpretation of these findings. Interestingly, VAP was not associated with mortality in the only
2 populations that had limited heterogeneity, namely, trauma
(OR, 1.09 [95% CI, 0.87–1.37]) and acute respiratory distress
syndrome (OR, 0.86 [95% CI, 0.72–1.04]).9
Collectively, current and previous2-5 findings have important clinical implications because they suggest that VAP continues to be associated with a substantial resource utilization
burden, which can be used to justify the use of preventive
strategies. In addition to reducing the incidence of VAP, the
ideal strategy should not increase healthcare costs or burden
healthcare providers.10,11 Examples of strategies shown to reduce the incidence of VAP and to be cost effective include
multifaceted preventive bundles,12-14 which include education,
semirecumbent positioning, good oral hygiene, and other infection control practices.
Our study had several limitations. It was subject to the
inherent bias of retrospective analysis; however, the data were
collected prospectively. To limit bias, we matched patients at
the 4-digit propensity score precision level or higher. The
cohorts appeared to be balanced, as demonstrated by the lack
of differences in patient and hospital characteristics other
than discharge status. Including severity of illness as a variable
may have biased the matching process because VAP can
worsen this variable; however, this would have attenuated the

impact of VAP. The database did not include information on
preventive strategies or some risk factors for VAP, such as
supine positioning. We did not collect information on microbiology, detailed antibiotic use, or appropriateness of initial therapy and therefore could not assess the role of these
variables on outcome. We were not able to specifically link
all costs directly to VAP, such as incremental antibiotic costs.
We did not validate use of the new VAP diagnosis code against
patient charts or alternate database methods that relied on
post-MV initiation of treatment for pneumonia to identify
VAP. If the code lacked sensitivity as suggested by the low
VAP rate, our study population may not be representative of
patients with VAP; however, this limitation would have attenuated the impact of VAP on economic findings. Our findings do not prove that VAP caused the observed increased
LOS; it is possible that the increased duration of hospitalization caused the increased risk of infection, an inherent
limitation of epidemiologic studies of time-dependent events
such as VAP.15
In conclusion, our findings suggest that VAP continues to
occur amidst lack of agreement regarding diagnostic criteria
and the exact prevalence. More importantly, VAP continues
to be associated with a statistically significant resource utilization burden. Therefore, hospitals should attempt to target
patients at risk for VAP with cost-effective interventions
aimed at minimizing the occurrence of this complication.
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